GlassScriptPhysician profile
Jarred P Reed
NPI 1013250869
$5,032.24
in general payments reported to CMS, 2019-2025
34 companies · $842 in 2025
The $842 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $233 · 2021: $35.99 · 2022: $122 · 2023: $350 · 2024: $2,945 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,625 · Food and Beverage: $1,146 · Honoraria: $350 · Education: $16.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,625.00 |
| Food and Beverage | $1,146.12 |
| Honoraria | $350.00 |
| Education | $16.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,640.06 | 2024 | Imfinzi, Enhertu |
| Regeneron Pharmaceuticals, INC. | $350.00 | 2025 | Lynozyfic |
| Celgene Corporation | $262.47 | 2021-2025 | Reblozyl, Pomalyst |
| Genentech USA, INC. | $221.83 | 2020-2025 | Tecentriq, Columvi |
| Lilly USA, LLC | $161.78 | 2019-2025 | Retevmo, Jaypirca, Verzenio |
| Seagen INC. | $161.35 | 2019-2023 | Adcetris, Tukysa |
| Alexion Pharmaceuticals, INC. | $152.68 | 2019-2024 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $119.51 | 2019-2025 | Libtayo |
| Incyte Corporation | $89.52 | 2019-2025 | Jakafi |
| Abbvie INC. | $70.76 | 2019-2025 | |
| Janssen Biotech, INC. | $70.61 | 2019-2025 | Rybrevant, Talvey, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $57.62 | 2019-2025 | Opdualag |
| Pfizer INC. | $53.79 | 2019-2022 | |
| Adc Therapeutics America, INC. | $49.51 | 2023-2025 | |
| Genzyme Corporation | $45.68 | 2019-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $43.93 | 2024 | |
| Eisai INC. | $40.10 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $39.64 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.02 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.97 | 2020-2024 | Fruzaqla |
| Dendreon Pharmaceuticals LLC | $29.91 | 2025 | Provenge |
| Immunogen, INC. | $29.21 | 2023 | Elahere |
| Amgen INC. | $28.75 | 2020 | |
| Tersera Therapeutics LLC | $28.70 | 2023 | Xermelo |
| Merck Sharp & Dohme LLC | $28.11 | 2025 | Keytruda |
| Ipsen Biopharmaceuticals, INC | $26.22 | 2025 | Onivyde |
| Mirati Therapeutics, INC. | $23.61 | 2024 | Krazati |
| Lexicon Pharmaceuticals, INC. | $23.19 | 2019 | |
| Stemline Therapeutics INC. | $22.43 | 2025 | Elzonris |
| Puma Biotechnology, INC. | $20.15 | 2019 | |
| Array Biopharma INC | $18.36 | 2025 | Braftovi, Lorbrena, Xalkori |
| Agios Pharmaceuticals, INC. | $18.24 | 2025 | Pyrukynd |
| Sanofi-Aventis U.S. LLC | $16.33 | 2019 | |
| Foundation Medicine, INC. | $15.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jarred Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.